Amsel Medical Announces Appointment of Jeff Willis as Senior Director of Engineering
Experienced executive brings track record of quality product develop for growth
Cambridge, Mass. -- Amsel Medical Corp. today announced the appointment of Jeff Willis as Senior Director of Engineering to help drive the current product commercialization phase and implement the company’s strategy to address the demand for minimally invasive, simple and secure occlusion.
“Jeff is an exceptionally focused engineer and executor,” said Amsel Medical CEO David Doster. “He brings a consistent reputation for delivering quality products that serve market needs and are tailored to physician demand.”
Most recently, Willis was a Director of Quality Assurance for Medline Industries. Previous to this he served at AngioDynamics including as Director of Research and Development, Manufacturing Engineering and Quality Assurance. Prior to that, he served as a quality assurance and manufacturing engineer at C.R. Bard. He earned a Bachelor of Science Degree in Chemical Engineering from Cornell University.
“I’ve seen the priority Amsel Medical places on quality as a cornerstone for addressing physician demand for better and easier closure technology,” said Willis. “It is exciting to join a team that is designing and delivering products engineered to address critical patient needs with physician driven solutions.”
Amsel Medical’s SCureClamp™ with Interdigitation Occlusion Technology (iDOT™) is designed to easily and securely close vessels – veins, arteries, and tubular structures including ducts – for surgical and interventional procedures.
About Amsel Medical Corporation
Amsel Medical Corporation is a medical device venture delivering simple and secure technology for vessel and duct closure. Its CE mark and FDA cleared SCureClamp™ with Interdigitation Occlusion Technology (iDOT™) is designed to easily and securely close vessels – veins, arteries, and tubular structures like ducts – for surgical and interventional procedures. The unique mechanical surgical clamping technology is delivered directly through a fine, minimally invasively, 18G needle. iDOT’s anchoring feature secures the implant in place and eliminates slippage. Grasping allows physicians to occlude vessels of varying sizes, types and wall thickness.